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Abstract Camel milk (CM) has good nutritive value, in addition to its antigenotoxic and anticy-
totoxic effects. Therefore the aim of this investigation was to evaluate the capacity of CM to inhibit
the micronucleated polychromatic erythrocytes (MnPCEs) in the bone marrow and improve the
mitotic activity produced by cisplatin. Cisplatin is one of the most widely used antineoplastic drugs
in the treatment of cancer. The 70 adult male Swiss albino mice were divided into seven groups:
Gr. I: treated with distilled water and considered as a control group.
Gr. II: treated with camel milk (33 ml/kg, b.w).
Gr. III: treated previously with cisplatin (0.5 mg/kg, b.w).
Gr. IV: treated with camel milk and followed after 2 h. with cisplatin (33 ml/kgﬁ 0.5 mg/
kg, b.w).
Gr. V: treated with camel milk and cisplatin at the same time (33 ml/kg + 0.5 mg/kg, b.w).
Gr. VI: treated with an acute single dose of cisplatin (2.5 mg/kg, b.w).
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Gr. VII: treated with camel milk prior and followed with an acute single dose of cisplatin
(33 ml/kgﬁ 2.5 mg /kg, b.w). The animals were sacriﬁced 24 h after cisplatin injection. The
pretreatment with CM dose caused a signiﬁcant decrease (P< 0.001) in the frequency of
MnPCEs and increase (P< 0.001) in the mitotic index (MI) induced by cisplatin when com-
pared with the groups treated with cisplatin alone. The possible explanation for the antigen-
otoxic and anticytotoxic effects observed in the pretreatment with CM is ascribed to its
contents. In conclusion, from the ﬁndings we suggest that this milk has some antioxidant
effect, and the antigenotoxic mechanism of this milk needs to be explored further before their
use during cisplatin chemotherapy.
ª 2010 King Saud University. All rights reserved.
1. Introduction Konuspayeva et al., 2004). Therefore, the aim of this work is
to study the possible protective role of camel milk against
the genotoxic effects of cisplatin.
2. Materials and methods
2.1. Animals
Male Swiss albino mice (Mus musculus), MFI strain, 8–9 weeks
old, weighed 25–30 g, were obtained from the animal house of
King Fhad Medical Research Center. Animals were housed in
polyplastic cages with steel wire tops in an air conditioned
room (22 ± 1 C, 45–75% relative humidity) maintained in a
controlled atmosphere of 12 h light/12 h dark cycles. Food
and water were provided ad libitum.
2.2. Test compound
2.2.1. Cisplatin
Cis-diamminedichloroplatinum-II Cisplatin (Cis-DDP) was
purchased in the form of a solution dissolved in distilled water
(CAs No. 781520-03) under the trade name cisplatinum (EBE-
WE Pharma, Austria). The cisplatin dose was determined
according to the human therapeutic dose (sub-acute dose
20 mg/m2 and acute dose 100 mg/m2), taking into consider-
ation the relative body weight and surface area of the mice rel-
ative to that of an adult human being.
2.2.2. Camel milk
2.2.2.1. Sampling of milk. Camel milk samples were collected
from three lactating camels of the same breed, the camels were
in 3.5–4 months of lactation. Camels were of the C. Hamra
breed dromedaries. All lactating camels consumed the same
type of feed (barley and Lucerne). Female camels were selected
from a local farm in Usfaan region, Jeddah. The milk was col-
lected in the morning.
Samples were collected in bottles and kept on ice during
transportation to the laboratory where they were stored at 3 C.
2.3. Treatment, doses and route of administration
Cisplatin was administered both sub-acutely by a single intra-
peritoneal injection (i.p.) for ﬁve consecutive days and acutely
by a single intraperitoneal injection (i.p.). In sub-acute treat-
ment the therapeutic dose of cisplatin was 20 mg/m2, while
in sub-acute treatment was 100 mg/m2. The doses were ad-
justed for mice according to Paget and Barnes (1964). The
doses for mice were 0.5 mg/kg and 2.5 mg/kg, respectively.
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many forms of human cancers. However, as with many agents
that have mammalian cell toxicity as a target, physiological
side effects can occur and genotoxic effects can be induced in
non-tumor cells that can give rise to secondary tumors (Beret-
ta, 1991). The intake of food with chemopreventive constitu-
ents has been recommended as an effective strategy for
strengthening our defense against the deleterious effect of
genotoxins and carcinogens (Ramel et al., 1986).
Cisplatin is one of the most widely used cytostatic agents in
the treatment of patients with solid tumor which induced
nephropathy, hearing loss and neurotoxicity (Rosenberg,
1985). The clastogenic potential of cisplatin has been of great
interest because of its serious effects on the chromosomes of
non-tumor cells. In patients treated with cisplatin for a long-
term, genetic damage can be observed during chemotherapy
or many years later (Elsendoorn et al., 2001). The clastogenic-
ity of this drug in humans and experimental animals has been
well documented. Cisplatin induced the micronuclei in bone
marrow cells and chromosomal aberrations in the germinal
cells of mice (e.g. Kliesch and Adler, 1987; Adler and El-
Tarras, 1989), and the micronuclei in peripheral blood
lymphocytes of testicular patients with various type of cancer
(Osanto et al., 1991; Elsendoorn et al., 2001).
The available evidence has shown that many dietary prod-
ucts are anticlastogen agents (Ferguson, 1999).
Camel’s milk (CM) is an excellent source of well balanced
nutrients and also exhibits a range of biological activities that
inﬂuence digestion, metabolic responses to absorbed nutrients,
growth and development of speciﬁc organs and resistance to
diseases. These biological activities are mainly due to the pres-
ence of peptides and protein in milk (Yagil et al., 1984; Korho-
nen and Pihlanto, 2001). Casein is the principal protein
component in most of the mammalian milk. Besides casein
CM also contains lactoferrin protein. CM is low in fat, high
in protein and vitamin C than cow’s milk. It also contains
fat with a relatively large amount of polyunsaturated fatty
acids and linoleic acids, which are essential for human nutri-
tion (Gorban and Izzeldin, 2001). There are high levels of lin-
oleic acids (18:2) among the polyunsaturated fatty acids in
camel milk (Crawford et al., 1976). The anticytoxic and anti-
genotoxic effects of most of the CM constituents against the
genotoxic effects of chemicals are being investigated (e.g. vita-
min C: Krishna et al., 1986; Vijayalaxmi and Venu, 1999; Rao
et al., 2001; Selenium: Hurna´ et al., 1997; Cabrera et al., 2003;
Hassan et al., 2006, Zinc: Hurna´ and Hurna´, 2000; Casein:
Van Boekel et al., 1993; Goeptar et al., 1997; Lactoferrin:
The control animals received an equal volume of the sol-
vent by intraperitoneal injection (i.p.) for ﬁve consecutive days.
The route of administration for camel milk was oral intuba-
tion (o.i.) for ﬁve consecutive days. The camel milk dose was
found to be 33 ml/kg after some preliminary experiments.
2.4. Experiment design
Male mice were randomly divided into seven groups of ten ani-
mals each. Animals in group one (Gr. I) were given the solvent
(i.p.), in group two (Gr. II) the camel milk (o.i) 33 ml/kg, in
group three (Gr. III) the cisplatin 0.5 mg/kg (i.p.), in group
four (Gr. IV) the sub-acute pretreatment of camel milk (o.i.)
2 h before cisplatin (0.5 mg/kg) for ﬁve consecutive days, in
group ﬁve (Gr. IV) the simultaneous treatment with camel
milk (o.i.) and cisplatin (0.5 mg/kg) (i.p.), in group six (Gr.
VI) the acute treatment of cisplatin (2.5 mg/kg) and in group
seven (Gr. VII) sub-acute treatment of camel milk (o.i.) fol-
lowed by an acute treatment with cisplatin (2.5 mg/kg) 2 h
after the ﬁfth administration of camel milk.
2.5. Procedure
2.5.1. Slides preparation for micronucleus (MN) and mitotic
index (MI)
The mouse micronucleus test was carried out according to Sch-
mid (1973, 1975) with some modiﬁcation in ﬁxation and stain-
ing based on the method of Heddle et al. (1984).
Animals were scariﬁed 24 h after the last treatment either for
sub-acute or acute treatment. Both the femora were removed
and stripped clean of muscles. The bone marrow was pushed
out with a pin, placed on a microscope slide and mixed with
drops of fetal calf serum. The cells were then smeared and al-
lowed to dry. The slides were ﬁxed in absolute methanol for
5 min and stained for 10 min in a 5% solution of Giemsa in
0.01 phosphate buffer adjusted to PH 6.8 and mounted in DPX.
2.5.2. Scoring
Stained preparations were coded and scored by a light micro-
scope at 1000· magniﬁcation.
2.5.2.1. Micronucleus (MN). One thousand polychromatic
erythrocytes (PCEs) were scored per animal for determining
the frequency of micronucleated poly-chromatid erythrocytes
(MnPCEs).
Micronuclei were identiﬁed according to Schmid (1975),
Hayashi et al. (1984) and Albanese and Middleton (1987) cri-
teria. They were morphologically identical to the normal nuclei
but smaller than them (their diameter 1/5 of the main nuclei)
Fig. 1.
2.5.2.2. Mitotic index (MI). The MI was scored in the same
slides of MN by calculating the number of dividing cells
(including prophase, metaphase and anaphase) in a population
of 1000 cells.
2.6. Statistical analysis
The student t-test analysis of variance (ANOVA) followed by
low signiﬁcant difference (LSD) were used for statistical anal-
ysis of the data. The results were expressed as mean ± stan-
dard deviation (SD) for MN and MI data and were
compared with controls (saline and camel milk) by student’s
t-test and the minimum level of signiﬁcance accepted being
at p< 0.05.
The difference in the total number of MN and MI was ana-
lysed statistically by (ANOVA) with calculation of the ‘‘F’’ sta-
tistics and its p value.
2.7. Protective effect
The protective index of camel milk (CM) against the clasto-
genic and cytotoxic effects of cisplatin on the induction of
MN and MI was calculated according to the equation of Shu-
kla and Taneja (2002) as follows:
100 %MNðCMþ Cis-DDPÞ groups
%MNðCis-DDPÞ groups
 
 100
100 %MIðCMþ Cis-DDPÞ groups
%MIðCis-DDPÞ groups
 
 100
3. Results
3.1. Micronucleus (MN)
The results obtained are shown in Tables 1 and 2. Table 1 pre-
sents the effect of CM (Gr. II) dose on the number of micro-
nucleated polychromatic erythrocytes (MnPCEs) in the bone
marrow cells of male mice treated with cisplatin (Gr. III and
Gr. VI).
Table 1 shows that a sub-acute pretreatment of CM (33 ml/
kg) slightly increases the number of MnPCEs, however, this in-
crease did not reach the signiﬁcant level when compared with
the control group (Gr. I).
Both sub-acute (Gr. III) and acute (Gr. VI) treatments of
therapeutic doses, 0.5 mg/kg and 2.5 mg/kg, respectively, of
cisplatin induced signiﬁcant increase (p< 0.001) in the num-
bers of MnPCEs in comparison with the control group.
With respect with the inhibitor effect of MN on MnPCEs
induced either by sub-acute dose (0.5 mg/kg) or acute dose
(2.5 mg/kg) of cisplatin. Table 1 shows that the dose of CM
produced a statistically signiﬁcant reduction of the micronuclei
number along the evaluated schedule.Figure 1 The micronucleated polychromatic erythrocyte.
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A statistical decrease (p< 0.001) in the number of MnP-
CEs was detected after the sub-acute pretreatment of CM dose
(33 ml/kg) before sub-acute dose (0.5 mg/kg) of cisplatin (Gr.
IV) from 8.61% to 4.28%, whereas a statistically signiﬁcant
decrease (p< 0.01) was recorded after the simultaneous treat-
ment of CM dose and sub-acute dose of cisplatin from 8.61%
to 6.29% when compared with Gr. III (0.5 mg/kg of cisplatin).
On the other hand the sub-acute treatment of CM dose fol-
lowed by the acute dose of cisplatin (2.5 mg/kg) (Gr. VII) in-
duced a signiﬁcant decrease (p< 0.001) in the number of
MnPCE from 9.77% to 3.72%.
Therefore, the administration of CM resulted in a decrease
in cisplatin induced increase in the number of MnPCEs, indi-
cating a protective effect of about 50.29% in Gr. IV, 26.95%
in Gr. V and 61.92 in Gr. VII.
3.2. Mitotic index (MI)
The results obtained for MI are shown in Table 2.
Sub-acute pretreatment with a single dose of CM at the
dose of 33 mg/kg (Gr. II) was not cytotoxic since no signiﬁcant
difference was observed between the mitotic indices from the
pretreatment and control group (Table 3).
In Gr. III and Gr. VI a statistically signiﬁcant decrease
(p< 0.001) in MI was observed when compared to Gr. I indi-
cating a cytotoxic response of a sub-acute dose of 0.5 mg/ kg
and an acute dose of 2.5 mg/kg of cisplatin (Table 3). The
mean ± SD of mitotic indices were found to be 21.30 ± 1.93
and 17.10 ± 1.35 in Gr. III and Gr. VI, respectively, and ele-
vated to 43.30 ± 1.72, 38.00 ± 2.43, 34.80 ± 1.99 in Gr. IV,
Gr. V and Gr. VII, respectively. The calculated protective ef-
fect was 103.29%, 87.4% and 103.51% in Gr. IV, Gr. V and
Gr. VII, respectively.
Tables 3 and 4 show the results of ANOVA and LSD ob-
tained with respect to the rate of MnPCEs and MI produced
by CM along the experiment.
There were signiﬁcant differences (p< 0.001) between the
mean of induction of MnPCE (F= 36.56) and MI
(F= 36.49) obtained from the sub-acute treatment of CM
dose (Gr. II) or sub-acute dose of cisplatin (Gr. III) and pre-
treatment Gr. IV (33 ml/kgﬁ 0.5 mg/kg) or simultaneous
treatment Gr. V (33 ml/kg + 0.5 mg/kg) of CM and the drug
in comparison with the control group (Gr. I). In the case of
pretreatment of CM dose (Gr. II) followed by the acute dose
(2.5 mg/kg) of cisplatin (Gr. VI), the F values were 86.90,
69.42 p< 0.001 for MN and MI, respectively.
Table 2 Effect of pretreatment of camel milk (CM) on the mitotic index of male mice bone marrow cells treated with cisplatin.
Groups Treatment and dose No. of examined
mice
No. of examined
cells
Total no. of
dividing cells
Mean ± SD % of Mitotic
index
% Protective
index
Gr. I Control 10 1000 549 54.90 ± 2.80 5.49 –
Gr. II CM (33 ml/kg) 10 1000 520 52.00 ± 1.99 5.20 –
Gr. III Cis-DDP (0.5 mg/kg) 10 1000 213 21.30 ± 1.93a*** 2.13 –
Gr. IV CMﬁ Cis-DDP (0.5 mg/kg) 10 1000 433 43.30 ± 1.72b*** 4.33 103.29
Gr. V CM+ Cis-DDP (0.5 mg/kg) 10 1000 380 38.00 ± 2.43b*** 3.80 78.4
Gr. VI Cis-DDP (2.5 mg/kg) 10 1000 171 17.10 ± 1.35a*** 1.71 –
Gr. VII CMﬁ Cis-DDP (2.5 mg/kg) 10 1000 348 34.80 ± 1.99c*** 3.48 103.51
*p< 0.05.
**p< 0.01.
*** p< 0.001.
a Statistically compared with Gr. I.
b Statistically compared with Gr. III.
c Statistically compared with Gr. VI.
Table 1 Effect of camel milk (CM) pretreatment on MN induced by cisplatin in bone marrow polychromatic erythrocytes (PCEs) of
male mice.
Groups Treatment and dose No. of examined
mice
No. of examined
PCEs
No. of
MnPCEs
Mean ± SD % of
MN
% Protective
index
Gr. I Control 10 1000 235 23.50 ± 2.72 2.35 –
Gr. II CM (33 ml/kg) 10 1000 288 28.80 ± 1.80 2.88 –
Gr. III Cis-DDP (0.5 mg/kg) 10 1000 861 86.10 ± 5.24a*** 8.61 –
Gr. IV CMﬁ Cis-DDP (0.5 mg/kg) 10 1000 428 42.80 ± 5.14b*** 4.28 50.29
Gr. V CM+ Cis-DDP (0.5 mg/kg) 10 1000 629 62.90 ± 5.16b** 6.29 26.95
Gr. VI Cis-DDP (2.5 mg/kg) 10 1000 677 97.70 ± 5.68a*** 9.77 –
Gr. VII CMﬁ Cis-DDP (2.5 mg/kg) 10 1000 372 37.20 ± 3.41c*** 3.72 61.92
*p< 0.05.
** p< 0.01.
*** p< 0.001.
a Statistically compared with Gr. I.
b Statistically compared with Gr. III.
c Statistically compared with Gr. VI.
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According to LSD the arrangement of treatments was:
1. Cis-DDP (0.5 mg/kg) > CM+ Cis-DDP > CMﬁ Cis-
DDP > CM (33 ml/kg).
2. Cis-DDP (2.5 mg/kg) > CM ﬁ Cis-DDP > CM (33 ml/
kg) for MN and MI.
4. Discussion
Cisplatin is a heavy metal complex with two labile chloride
groups which upon hydrolysis in aqueous solution form vari-
ous reactive oxygen species, such as superoxide anion, by inter-
action with DNA (Masuda et al., 1994; Baliga et al., 1998).
The clastogenic effect of cisplatin has already been described
(Adler and El-Tarras, 1989; Krishnaswamy and Dewey,
1993; Jirsova´ and Mandys, 1994; Edelweiss et al., 1995; Cho-
udhury et al., 2000).
In the present study, i.p. doses (0.5 mg/kg and 2.5 mg/kg) of
cisplatin were clastogenic, which was determined by the cyto-
genetic parameter, such as an extremely statistically signiﬁcant
increase in the number of micronucleated polychromatic eryth-
rocytes (MnPCEs). These results were corroborated by previ-
ous studies on mice and rat bone marrow cells (Ciri et al.,
1998; Choudhury et al., 2000; Choudhury and Jagdale, 2002;
Khynriam and Prasad, 2003).
The CM administration route was oral, probably most
appropriate because it is the same route as that of human
exposure. It is worth mentioning that the dose of CM did
not cause anincrease in the percentage of MnPCEs or a de-
crease in the percentage of MI compared with the respective
control groups.
The combined treatments of administering CM either be-
fore or during simultaneous injection with sub-acute (0.5 mg/
kg) or before acute (2.5 mg /kg) therapeutic doses of cisplatin
showed a signiﬁcant (p< 0.001) decrease in the frequency of
MnPCEs and increase in the mitotic index when compared
with cisplatin alone. The data obtained show that the CM dose
has anticlastogenic and anticytotoxic effects against the cis-
platin-induced increase in the MnPCEs and decrease in the
MI in bone marrow cells. However, the MnPCEs and MI in
the animals treated with the combination of cisplatin and
CM did not reach the control level or CM-treated groups.
An appropriate explanation of this anticlastogenicity or
anticytotoxicity is not easy because the tested agent is a mix-
ture of several constituents that may participate in the ob-
served effect.
Table 3 Analysis of variance ‘‘ANOVA’’ and low signiﬁcant differences ‘‘LSD’’ between the effects of sub-acute pretreatment of
camel milk (CM) or sub-acute dose (0.5 mg/kg) or acute dose (2.5 mg/kg) of cisplatin and pre-simultaneous treatments of CM and sub-
acute dose and acute dose of cisplatin on the frequency of MN induction in bone marrow polychromatic erythrocytes (MnPCEs) of
male mice.
Treatments (dose mg/kg) Control group ANOVA LSD
F Groups Treatment of dose Mean diﬀerence Sig
Sub-acute treatment (0.5 mg/kg) I 36.56*** II CM 5.30
III Cis-DDP (0.5 mg/kg) 62.60 ***
IV CMﬁ Cis-DDP 19.30 **
V CM+ Cis-DDP 39.40 ***
Acute treatment (2.5 mg/kg) I 86.90*** II CM 5.30
VI Cis-DDP (2.5 mg/kg) 74.20 ***
VII CM+ Cis-DDP 13.70 *
* p< 0.05.
** p< 0.01.
*** p< 0.001.
Table 4 Analysis of variance ‘‘ANOVA’’ and low signiﬁcant differences ‘‘LSD’’ between the effects of sub-acute pretreatment of
camel milk (CM) or sub-acute dose (0.5 mg/kg) or acute dose (2.5 mg/kg) of cisplatin and the pre- and simultaneous treatments of CM
and sub-acute dose on the mitotic index in bone marrow cells of male mice.
Treatments (dose mg/kg) Control group ANOVA LSD
F Groups Treatment of dose Mean diﬀerence Sig
Sub-acute treatment (0.5 mg/kg) I 36.49*** II CM 2.90
III Cis-DDP (0.5 mg/kg) 33.60 ***
IV CMﬁ Cis-DDP 11.60 **
V CM+ Cis-DDP 16.90 ***
Acute treatment (2.5 mg/kg) I 69.42*** II CM 2.90
VI Cis-DDP (2.5 mg/kg) 37.80 ***
VII CM+ Cis-DDP 20.10 ***
*p< 0.05.
** p< 0.01.
*** p< 0.001.
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Camel’s milk is low in fat, high in protein and vitamin C
than cows’ milk.
Farah et al. (1992) reported that the vitamin C content in
camel’s milk is about three times higher than that in cows’
milk. The high level of vitamin C in camel milk has been con-
ﬁrmed by several studies (Rao et al., 1970; Kon, 1972; Knoess,
1977; Sohail, 1983; Sawaya et al., 1984; Khanna, 1986; Yagil,
1982; Farah et al., 1992; Mehaia, 1994).
The anticlastogenic and even antimutagenic role of vitamin
C (L-ascorbic acid) has been tested in a variety of in vivo and
in vitro systems treated or exposed to – mitomycin C (MMC)
(Krishna et al., 1986), pesticides (Hoda and Sinha, 1993), ble-
omycin (BLM) (Povirk and Austin, 1991; Anderson et al.,
1995), radiation (Castillo et al., 2000) and rifampicin (RMP)
antibiotic (Aly and Donya, 2002). Vitamin C is a strong anti-
oxidant (Rao, 1997; Sato et al., 1997). The detoxiﬁcation effect
of vitamin C is manifested by the removal or minimization of
free radicals produced by mercury (Gebhart, 1984; Herba-
czyn´ska et al., 1995). Vitamin C has nucleophilic properties
and binds to mercury ions (Hg2+) to reduce the mercury-in-
duced DNA damage (Rao et al., 2001).
Ascorbic acid protects DNA from oxidative damage (Eylar
et al., 1996; Antunes and Takahashi, 1999), reduces DNA
damage exerted by irradiation (Green et al., 1994) and also re-
duces micronucleus (MN) frequencies in polychromatic eryth-
rocytes of bone marrow in rodents exposed to heavy metals
and radiation (Chorvatovicova´ et al., 1991; Konopacka
et al., 1998).
Al-Awadi and Srikumar (2001) analysed the concentration
and distribution of trace elements in camel milk compared to
those in human and cow milk. They found that the selenium
content of CM was comparable to those of other types of milk.
Iana˘s et al. (1995) described the all round beneﬁcial action
of selenium preparation in rats exposed to carbon tetrachloride
(CCl4), as well as a strong antioxidant effect, conﬁrming the
essential role of selenium in maintaining cellular integrity.
Moreover, the protective effect of selenium against cadmium
genotoxicity in the Chinese hamster V79 cells was reported
by Hurna´ et al. (1997). Selenium is a constituent of various oxi-
dant defense selenioproteins and a cofactor of glutathione per-
oxidase in the elimination of peroxide radicals; selenium also
seems to prevent cancer development (Cabrera et al., 2003).
The characteristic feature of supplemental selenium to reduce
the genotoxic effect of cobalt chloride (CoCl2) was proved
by Hassan et al. (2006).
The zinc content of camel’s milk was higher than that of hu-
man milk (AL-Awadi and Srikumar, 2001). The protective ef-
fect of zinc on cadmium genotoxicity (the number of
micronucleated cells decreased) was observed at a lower con-
centration (5–25 micro M cdcl2) (Hurna´ and Hurna´, 2000).
Zinc is an element required for DNA and RNA synthesis
and may be a cofactor in the activity of superoxide dismutase
(Cabrera et al., 2003).
Furthermore, milk exhibits a range of biological activities.
These biological activities are mainly due to peptides and pro-
tein in milk. Bioactive peptides are produced during the diges-
tion of milk in the gastrointestinal tract (Korhonen and
Pihlanto, 2001). The beneﬁcial health effects of milk proteins
can be classiﬁed as antimicrobial, antioxidative, antithrom-
botic, antihypertensive or immuno-modulatory (FitzGerald
and Meisel, 2000; Kohonen and Pihlanto, 2003).
The average content of protein (Casein and whey proteins)
in camel’s milk is generally similar to that of cows milk,
whereas human milk has the lowest protein content among
the milk from other mammals (Jenness, 1974). Casein is the
principal protein component of the most milk from most of
the mammals.
The antimutagenic potential of casein was investigated by
Van Boekel et al. (1993) using several mutagens. They found
that preincubation increased the antimutagenic potential of
casein towards N-nitroquinoline-1-oxide (NQO). They added
that the antimutagenic potential of casein increased with pep-
sin hydrolysis. They postulated that this increase was due to
the peptides formed and might be explained by a better acces-
sibility of casein peptides for interaction with mutagens.
In addition, Bosselaers et al. (1994) studied the possible
antimutagenic effect of ﬁve different proteins including casein.
They found that casein signiﬁcantly inhibited 4-nitroquinoline
1-oxide (4-NQO) and 1-methyl-1-nitroso-3-nitroguanidine
(MNNG) induced sister chromatid exchange (SCE). They also
reported that pepsin-hydrolysed casein inhibited SCE induc-
tion by 4NQO and MNNG. Therefore, they concluded that
casein and its pepsin hydrolysis products may protect mamma-
lian cells against certain genotoxic compounds. They added,
although the mechanism of antimutagenicity is unknown, it
seems believable that the protein acts as a blocking agent by
chemical or physical interaction with the mutagens. They
added that the accessibility of protein molecules and the pres-
ence of nucleophilic binding sites may be signiﬁcant factors in
determining the antimutagenic properties of proteins. More-
over, Goeptar et al. (1997) presented that enzymatic digestion
of sodium caseinate greatly improved its antimutagenicity po-
tential. They suggested that the molecular structure of a pro-
tein determines the protective effect against mutagens. They
added that a stronger protection appears to correspond with
a lack of secondary and tertiary structure. Their ﬁndings shed
new light on the possible prevention of mutagenesis and/or
carcinogenesis by food proteins, with a unique role for milk
proteins.
Besides casein, camel milk contains high levels of lactofer-
rin. Lactoferrin is a iron-binding glycoprotein of the transfer-
rin family (Al-Majali et al., 2007). This relatively recent known
protein has a number of properties such as antibactericidal
activity, antiviral, antifungal, anticarcinogenic, anti inﬂamma-
tory activity, antioxidant and analgestic properties (Konuspay-
eva et al., 2004). A comparative survey of lactoferrin
concentrations in different milks showedthat camel’s milk con-
tain the greatest amount of lactoferrin (Konuspayeva et al.,
2004). There are high levels of linoleic acids (18:2) among
the polyunsaturated fatty acids in camel milk (Crawford
et al., 1976). Conjugated linoleic acid ‘‘CLA’’ was identiﬁed
as a component of milk and dairy products for over 30 years
ago. It is formed as an intermediate in the course of the conver-
sion of linoleic acid into oleic acid in the rumen (Kritchevsky,
2000). CLA compounds could serve as useful food antioxi-
dants and provide additional value because of their potential
bioactivity in disease prevention (Badr El-Din and Omaye,
2007). The results obtained by Liew et al. (1995) supported a
mechanism involving the inhibition of carcinogen activation
by CLA, as opposed to direct interaction with procarcinogen,
scavenging of electrophiles or selective induction of phase I
detoxiﬁcation pathways.
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Moreover, Yang et al. (2001) concluded that CLA modu-
late phIP (2-amino-1-methyl-6-phenylimidazol [4,5-b] pyri-
dine) induced mutagenesis in a tissue-speciﬁc manner.
In conclusion, our study established a signiﬁcant decrease
in the micronuclei and improvement in the mitotic index of
bone marrow cells of male mice pretreated with camel milk,
as well as a strong capacity to trap free radicals originating
from cisplatin. Thus, from the ﬁnding we suggest that camel’s
milk has antioxidant effects and the anticlastogenesis mecha-
nisms of this milk should explored further before its use during
cisplatin chemotherapy.
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